– USA, MA – Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced the appointments of John Orwin, Dr. Anna Berkenblit (M.D.), and Tom Frohlich to its Board of Directors. John Orwin will take the role of Chair of the Board of Directors.
“Nested’s pipeline of high value, highly novel programs and targets is truly impressive, as are the team and culture that have been built in such a short period time,” said Mr. Orwin. “I am thrilled to take on this new role as chair of the company’s board of directors and look forward to working with the team as they advance their groundbreaking medicines to and through the clinic.”
About John Orwin
John Orwin currently serves as president and CEO of Atreca, a clinical-stage biotechnology company, and is on the board of directors of Travere Therapeutics, Cargo Therapeutics (board chair), and AnaptysBio (board chair). He was previously the CEO of Relypsa until its acquisition by Galenica, CEO of Affymax, and on the board of directors of Array BioPharma and Seagen. In building successful businesses and commercializing a range of blockbuster products, Mr. Orwin has held leadership roles in marketing, sales, and operations for Genentech, Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer, and Schering-Plough Corporation.
Mr. Orwin holds a master’s degree in business administration from New York University and a bachelor’s degree from Rutgers, The State University of New Jersey.
About Dr. Anna Berkenblit
Dr. Berkenblit has more than 20 years of experience in the clinical development of novel anticancer therapies in the life science industry. Most recently, she served as CMO at ImmunoGen where she led the development of the company’s novel, wholly-owned product candidates. Before ImmunoGen, Dr. Berkenblit was SVP of clinical development at H3 Biomedicine, and VP and head of clinical research at AVEO Oncology before that. Dr. Berkenblit also held positions of increasing responsibility at Wyeth/Pfizer, becoming VP, and neratinib asset team leader in the Pfizer Oncology Business Unit.
She earned an M.D. from Harvard Medical School and an M.M.Sc. in the clinical investigator training program at Harvard/MIT Health Sciences & Technology. Dr. Berkenblit completed her internship and residency at Brigham and Women’s Hospital and went on to a hematology/oncology fellowship at Beth Israel Deaconess Medical Center. She also led the Phase I oncology clinical trial program as part of the Dana-Farber/Harvard Cancer Center, before transitioning to industry.
About Tom Frohlich
Tom Frohlich brings more than 25 years of leadership experience across multinational pharmaceutical and emerging biotech companies. He co-founded Chinook Therapeutics in 2019 and served as COO until Chinook’s acquisition by Novartis. Since 2018, Mr. Frohlich has also served as an operating principal and subsequently as an entrepreneur-in-residence at Versant Ventures, a healthcare investment firm. Before Chinook, he was VP of business development at Arbutus Biopharma, where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Mr. Frohlich worked internationally at Johnson and Johnson and Merck in various roles leading commercial strategy across all stages of product development including the global launches of Telaprevir and STELARA (ustekinumab).
Mr. Frohlich holds a B.Sc. in biochemistry from the University of Victoria and an MBA from the University of Oxford.
About Nested Therapeutics
Nested Therapeutics is a biotechnology company focused on discovering and developing novel, targeted, small-molecule precision medicine therapies for patients with cancer by using mutation clusters to identify druggable pockets. With a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI, Nested is working to reach untapped mutations with the potential to improve outcomes for millions of patients.
For more information: https://nestedtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
